These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
844 related articles for article (PubMed ID: 31046082)
21. Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028. Varga A; Piha-Paul S; Ott PA; Mehnert JM; Berton-Rigaud D; Morosky A; Yang P; Ruman J; Matei D Gynecol Oncol; 2019 Feb; 152(2):243-250. PubMed ID: 30522700 [TBL] [Abstract][Full Text] [Related]
22. Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study. Mehnert JM; Bergsland E; O'Neil BH; Santoro A; Schellens JHM; Cohen RB; Doi T; Ott PA; Pishvaian MJ; Puzanov I; Aung KL; Hsu C; Le Tourneau C; Hollebecque A; Élez E; Tamura K; Gould M; Yang P; Stein K; Piha-Paul SA Cancer; 2020 Jul; 126(13):3021-3030. PubMed ID: 32320048 [TBL] [Abstract][Full Text] [Related]
23. Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study GY016. Gien LT; Enserro DM; Block MS; Waggoner S; Duska LR; Wahner-Hendrickson AE; Thaker PH; Backes F; Kidd M; Muller CY; DiSilvestro PA; Covens A; Gershenson DM; Moore KN; Aghajanian C; Coleman RL Gynecol Oncol; 2024 Jul; 186():61-68. PubMed ID: 38603953 [TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study. Yap TA; Nakagawa K; Fujimoto N; Kuribayashi K; Guren TK; Calabrò L; Shapira-Frommer R; Gao B; Kao S; Matos I; Planchard D; Chatterjee A; Jin F; Norwood K; Kindler HL Lancet Respir Med; 2021 Jun; 9(6):613-621. PubMed ID: 33836153 [TBL] [Abstract][Full Text] [Related]
25. Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study. Shah MA; Kojima T; Hochhauser D; Enzinger P; Raimbourg J; Hollebecque A; Lordick F; Kim SB; Tajika M; Kim HT; Lockhart AC; Arkenau HT; El-Hajbi F; Gupta M; Pfeiffer P; Liu Q; Lunceford J; Kang SP; Bhagia P; Kato K JAMA Oncol; 2019 Apr; 5(4):546-550. PubMed ID: 30570649 [TBL] [Abstract][Full Text] [Related]
26. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. Plimack ER; Bellmunt J; Gupta S; Berger R; Chow LQ; Juco J; Lunceford J; Saraf S; Perini RF; O'Donnell PH Lancet Oncol; 2017 Feb; 18(2):212-220. PubMed ID: 28081914 [TBL] [Abstract][Full Text] [Related]
27. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. Shitara K; Van Cutsem E; Bang YJ; Fuchs C; Wyrwicz L; Lee KW; Kudaba I; Garrido M; Chung HC; Lee J; Castro HR; Mansoor W; Braghiroli MI; Karaseva N; Caglevic C; Villanueva L; Goekkurt E; Satake H; Enzinger P; Alsina M; Benson A; Chao J; Ko AH; Wainberg ZA; Kher U; Shah S; Kang SP; Tabernero J JAMA Oncol; 2020 Oct; 6(10):1571-1580. PubMed ID: 32880601 [TBL] [Abstract][Full Text] [Related]
28. Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer. Hamanishi J; Mandai M; Ikeda T; Minami M; Kawaguchi A; Murayama T; Kanai M; Mori Y; Matsumoto S; Chikuma S; Matsumura N; Abiko K; Baba T; Yamaguchi K; Ueda A; Hosoe Y; Morita S; Yokode M; Shimizu A; Honjo T; Konishi I J Clin Oncol; 2015 Dec; 33(34):4015-22. PubMed ID: 26351349 [TBL] [Abstract][Full Text] [Related]
29. Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study. Leighl NB; Hellmann MD; Hui R; Carcereny E; Felip E; Ahn MJ; Eder JP; Balmanoukian AS; Aggarwal C; Horn L; Patnaik A; Gubens M; Ramalingam SS; Lubiniecki GM; Zhang J; Piperdi B; Garon EB Lancet Respir Med; 2019 Apr; 7(4):347-357. PubMed ID: 30876831 [TBL] [Abstract][Full Text] [Related]
30. Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study. Hansen AR; Massard C; Ott PA; Haas NB; Lopez JS; Ejadi S; Wallmark JM; Keam B; Delord JP; Aggarwal R; Gould M; Yang P; Keefe SM; Piha-Paul SA Ann Oncol; 2018 Aug; 29(8):1807-1813. PubMed ID: 29992241 [TBL] [Abstract][Full Text] [Related]
31. Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥10. Wainberg ZA; Fuchs CS; Tabernero J; Shitara K; Muro K; Van Cutsem E; Bang YJ; Chung HC; Yamaguchi K; Varga E; Chen JS; Hochhauser D; Thuss-Patience P; Al-Batran SE; Garrido M; Kher U; Shih CS; Shah S; Bhagia P; Chao J Clin Cancer Res; 2021 Apr; 27(7):1923-1931. PubMed ID: 33446564 [TBL] [Abstract][Full Text] [Related]
32. Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial. Carlino MS; Long GV; Schadendorf D; Robert C; Ribas A; Richtig E; Nyakas M; Caglevic C; Tarhini A; Blank C; Hoeller C; Bar-Sela G; Barrow C; Wolter P; Zhou H; Emancipator K; Jensen EH; Ebbinghaus S; Ibrahim N; Daud A Eur J Cancer; 2018 Sep; 101():236-243. PubMed ID: 30096704 [TBL] [Abstract][Full Text] [Related]
33. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Burtness B; Harrington KJ; Greil R; Soulières D; Tahara M; de Castro G; Psyrri A; Basté N; Neupane P; Bratland Å; Fuereder T; Hughes BGM; Mesía R; Ngamphaiboon N; Rordorf T; Wan Ishak WZ; Hong RL; González Mendoza R; Roy A; Zhang Y; Gumuscu B; Cheng JD; Jin F; Rischin D; Lancet; 2019 Nov; 394(10212):1915-1928. PubMed ID: 31679945 [TBL] [Abstract][Full Text] [Related]
34. Phase II Study of Pembrolizumab As First-Line, Single-Drug Therapy for Patients With Unresectable Cutaneous Squamous Cell Carcinomas. Maubec E; Boubaya M; Petrow P; Beylot-Barry M; Basset-Seguin N; Deschamps L; Grob JJ; Dréno B; Scheer-Senyarich I; Bloch-Queyrat C; Leccia MT; Stefan A; Saiag P; Grange F; Meyer N; de Quatrebarbes J; Dinulescu M; Legoupil D; Machet L; Dereure O; Zehou O; Montaudié H; Wierzbicka-Hainaut E; Le Corre Y; Mansard S; Guégan S; Arnault JP; Dalac S; Aubin F; Alloux C; Lopez I; Cherbal S; Tibi A; Lévy V; J Clin Oncol; 2020 Sep; 38(26):3051-3061. PubMed ID: 32730186 [TBL] [Abstract][Full Text] [Related]
35. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Marabelle A; Fakih M; Lopez J; Shah M; Shapira-Frommer R; Nakagawa K; Chung HC; Kindler HL; Lopez-Martin JA; Miller WH; Italiano A; Kao S; Piha-Paul SA; Delord JP; McWilliams RR; Fabrizio DA; Aurora-Garg D; Xu L; Jin F; Norwood K; Bang YJ Lancet Oncol; 2020 Oct; 21(10):1353-1365. PubMed ID: 32919526 [TBL] [Abstract][Full Text] [Related]